000625，突然火了！迎超200家机构调研

Core Viewpoint - The article discusses the recent institutional research activities of listed companies, highlighting the performance of stocks that were under institutional scrutiny and the implications of regulatory approvals for companies like Changan Automobile and Yipin Hong. Group 1: Institutional Research Activities - A total of 165 listed companies disclosed institutional research records during the week of December 15-19, with approximately half of these companies achieving positive returns [3]. - The stock with the highest increase from institutional research was Zhenyou Technology, which rose by 21.89%, while nine other companies, including Hangtian Zhizao and Hongmian Co., saw increases exceeding 10% [4]. - Popular companies under institutional research included Changan Automobile, Yipin Hong, and Boin Special Welding, with Changan receiving the most attention from 214 institutions [5][7]. Group 2: Changan Automobile - Changan Automobile received the first batch of L3 conditional autonomous driving model approvals from the Ministry of Industry and Information Technology on December 15, allowing its model, Deep Blue SL03, to conduct pilot tests in designated areas [6][7]. - The company began its L3 autonomous driving capability development in 2017 and aims to complete safety verification and promote industry standards rather than solely pursuing technological limits [9]. - Changan plans to initiate pilot applications with its partner, Changan Car Union Technology, in Q1 2026, following the implementation of relevant national regulations [10]. Group 3: Boin Special Welding - Boin Special Welding hosted four institutional research sessions during the week, with 107 institutions participating, focusing on its core equipment for anti-corrosion and wear-resistant welding [11][12]. - The company utilizes multiple welding technologies, including MIG, TIG, and laser welding, to address industry challenges in various sectors such as energy and environmental protection [13]. - Boin's production capacity at its Vietnam base includes one HRSG production line, which can produce approximately two sets of HRSG devices per year, depending on production schedules and resource availability [13]. Group 4: Yipin Hong - Yipin Hong conducted research with 119 institutions and announced plans to sell its stake in Arthrosi, which has attracted significant market attention [14][15]. - Post-transaction, Yipin will retain 100% rights to the AR882 drug pipeline in China and maintain priority for global production supply, with the deal expected to close in Q1 2026 after antitrust reviews [15].